Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13411447 | 0.87 | ALDH1A1 (0.32) | MAPK1ALDH1A1 | |
| SCHEMBL9972441 | 0.85 | — | — | |
| SCHEMBL6176534 | 0.84 | MAPK1 (0.40) | MAPK1ALDH1A1TSHRTDP1 | |
| SCHEMBL6175846 | 0.83 | — | — | |
| SCHEMBL14182576 | 0.83 | — | — | |
| SCHEMBL7424817 | 0.83 | — | — | |
| SCHEMBL7424822 | 0.83 | MAPK1 (0.33) | MAPK1 | |
| SCHEMBL8187296 | 0.81 | — | — | |
| SCHEMBL12744839 | 0.81 | CYP2C19 (0.32) | MAPK1 | |
| SCHEMBL13126000 | 0.81 | MAPK1 (0.31) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1011 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2023-02-16 | — | — | US | claimed |
| WO-2021216722-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | Atea Pharmaceuticals, Inc. (US) | 2021-10-28 | — | — | WO | claimed |
| US-10570088-B2 | Blood brain barrier-penetrating oximes for cholinesterase reactivation | HUMAN BIOMOLECULAR RES FOUNDATION (US) | 2020-02-25 | — | — | US | claimed |
| US-20170349538-A1 | Blood Brain Barrier-Penetrating Oximes for Cholinesterase Reactivation | Human BioMolecular Research Foundation (US) | 2017-12-07 | — | — | US | claimed |
| US-8921599-B2 | Processes for forming amide bonds and compositions related thereto | EMORY UNIVERSITY (US) | 2014-12-30 | — | — | US | claimed |
| US-20140051712-A1 | BLOOD BRAIN BARRIER-PENETRATING OXIMES FOR CHOLISTENERASES REACTIVATION | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2014-02-20 | — | — | US | claimed |
| EP-1979362-B1 | NOVEL SILANE COMPOUNDS AND USE THEREOF IN ORDER TO FUNCTIONALISE SOLID MEDIA AND IMMOBILISE BIOLOGICAL MOLECULES ON SAID MEDIA | COMMISSARIAT ENERGIE ATOMIQUE (FR) | 2010-12-15 | — | — | EP | claimed |
| US-20090005269-A1 | Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2009-01-01 | — | — | US | claimed |
| EP-0600161-A1 | Amino acid terminated polyesters having predetermined monomeric sequence | United States Surgical Corporation (US) | 1994-06-08 | — | — | EP | claimed |
| EP-0579173-A2 | Polyesters having predeterminated monomeric sequence | United States Surgical Corporation (US) | 1994-01-19 | — | — | EP | claimed |
| US-5256762-A | Polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-10-26 | — | — | US | claimed |
| US-5248761-A | Amino acid terminated polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-09-28 | — | — | US | claimed |
| EP-3494996-B1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 158P1D7 PROTEINS | AGENSYS INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12551499-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | AGENSYS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | AGENSYS, INC. (US) | 2026-01-01 | — | — | US | disclosed |
| US-5256762-A | Polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-10-26 | — | — | US | disclosed |
| US-5248761-A | Amino acid terminated polyesters having predetermined monomeric sequence | UNITED STATES SURGICAL CORPORATION (US) | 1993-09-28 | — | — | US | disclosed |
| US-4792560-A | ANTIALLERGENS; ANTIINFLAMMATORY AGENTS | RORER PHARMACEUTICAL CORPORATION (US) | 1988-12-20 | — | — | US | disclosed |
| EP-0196674-A2 | Hydroxamates as modulators of arachidonic acid metabolic pathways | USV PHARMACEUTICAL CORPORATION (US) | 1986-10-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005269-A1 | Novel Silane Compounds and Their Use in Functionalizing Solid Supports and Immobilizing Biological Molecules on These Supports | SELE, ELANE, EPCAM | MAPK1 4013/4885ALDH1A1 374/4885TSHR 3246/4885 |
| US-20260000604-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING ANTI-191P4D12 ANTIBODY DRUG CONJUGATES AND METHODS OF USE THEREOF | CD44, CA12, H1-10 | MAPK1 4480/4885ALDH1A1 3280/4885TSHR 2385/4885 |
| US-10570088-B2 | Blood brain barrier-penetrating oximes for cholinesterase reactivation | ACHE, BCHE, PYGB | MAPK1 3478/4885ALDH1A1 1236/4885TSHR 2012/4885 |
| US-20140051712-A1 | BLOOD BRAIN BARRIER-PENETRATING OXIMES FOR CHOLISTENERASES REACTIVATION | BCHE, ACHE, PYGB | MAPK1 3260/4885ALDH1A1 1908/4885TSHR 2320/4885 |
| US-12551499-B2 | Highly active compounds against COVID-19 | PNP, SLC29A2, MTAP | MAPK1 2672/4885ALDH1A1 1808/4885TSHR 3265/4885 |
| US-20230049294-A1 | STEREOSELECTIVE PROCESS OF MANUFACTURE OF PURINE PHOSPHORAMIDATES | NUDT1, PNP, ITPA | MAPK1 790/4885ALDH1A1 1210/4885TSHR 3591/4885 |
| US-20260034234-A1 | ANTIBODY DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | IGSF11, ARID2, DYNLL2 | MAPK1 4705/4885ALDH1A1 1803/4885TSHR 3069/4885 |
| US-20170349538-A1 | Blood Brain Barrier-Penetrating Oximes for Cholinesterase Reactivation | ACHE, BCHE, PYGB | MAPK1 3478/4885ALDH1A1 1236/4885TSHR 2012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.